Melatonin as biological response modifier in cancer patients

Anticancer Research

Volumn 18, Issue 2 B, 1998, Pages 1329-1332

  Neri, B ^a   De Leonardis, V ^a   Gemelli, M T ^a   Di Lorq, F ^a   Mottola, A ^a   Ponchietti, R ^a   Raugei, A ^a   Cini, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biological response modifiers; Cytokines; Melatonin; Pineal gland; Solid tumors

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CYTOKINE; EDETIC ACID; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; MELATONIN; NEUROHORMONE; NEUROPEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNORADIOMETRIC ASSAY; MACROPHAGE; MALE; MONOCYTE; NEUROENDOCRINE SYSTEM; ORAL DRUG ADMINISTRATION; PINEAL BODY; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; TUMOR CELL; WELLBEING;

ADULT; AGED; BIOLOGICAL RESPONSE MODIFIERS; CYTOKINES; FEMALE; HUMANS; INTERFERONS; MALE; MELATONIN; MIDDLE AGED; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031831115     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Herberman RB: Principles of tumor immunology. In: Textbook of Clinical Oncology. Holleb A.I, Fink D.J, Murphy G.P. (eds) Atlanta, American Cancer Society, pp 69-79, 1991.
2. Specter S, Friedman H: Immunosuppressive factors produced by tumors and their effects on the RES. In: The Reticuloendohelial System: a Comprehensive Treatise. Herberman R.B. and Friedman H. (eds). New York, Plenum Press 5: 315-326, 1983.
3. Varesio L: Suppressor cells and cancer: inhibition of immune function by macrophages. In: The Reticuloendothelial System: a Comprehensive Treatise. Herberman R.B. and Friedman H. (Eds). New York, Plenum Press 5: 217-256, 1983.
4. Penn I: Principles of tumor immunity: immunocompetence and cancer. In: Biologic Therapy of Cancer. De Vita VT, Hellman S, Rosaemberg SA (eds). New York, JB Lippincott Company, 1991.
5. Maestroni GJM, Conti A, Pierpaoli W: Role of the pineal gland in immunity. Melatonin enhances the antibody response via an opiatergic mechanism. Clin Exp Immunol 68: 384-391, 1987.
6. Das U.N. Melatonin: is it an endogenous anti-mutagenic, oncostatic, and anti-ageing molecule? Med Sci Res 22: 463-466, 1994.
7. Riley V: Psychoneuroendocrine influences on immuno-competence and neoplasia. Science 212: 1100-1109, 1981.
8. Shavit Y, Terman GW, Martin FC: Stress, opiod peptides, the immune system and cancer. J Immunol 135: 834-837, 1985.
9. Maestroni GJM: The immunoendocrine role of melatonin. J Pineal Res 14: 1-10, 1993.
10. Blask DE, Wilson ST: Melatonin and oncostatic signal transduction: evidence for a novel mechanism involving glutathione and nitric oxide. In: Advances in Pineal Research. Moller M. and Pevet P. (eds). John Libbey, London. Vol.8, pp. 465-471, 1994.
11. Poeggeler B, Reiter RJ, Tang DX, Chen LD, Manchester LC: Melatonin, hydroxyl radical-mediated oxidative damage and aging: a hypothesis. J Pineal Res 14: 151-168, 1993.
12. Fidler IJ, Poste G: Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Semin Immunophatol 5: 161-174, 1992.
13. Fidler IJ, Kleinerman ES: Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 2:937-943, 1984.
14. McNamara MJ, Alexander HL, Norton JA: Cytokines and their role in the pathophysiology of cancer cachexia. J Parent Enter Nutr 16 (Suppl): 505-509, 1992.
15. Mantovani G, Macciï A, Bianchi A et al: Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparson with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 25: 135-141, 1995.
16. Karnofsky DA, Burchenal JK: The clinical evaluation of chemotherapeutic agents. In: Evaluation of Chemotherapeutic Agents. Mc Leod A (ed) New York, Columbia University Press pp 191-205, 1949.
17. Tchekmedyian NS, Hickman M, Zahyna D: Effects of megestrol acetate on cancer patients: impact on palliative care and quality of life. In: Hormones in Cancer Cachexia. Hartenstein R, Tchekmedyian N.S. (eds) Munchen, Verlag Press pp 59-67, 1991.
18. Miller QAB, Hoogastraten B, Staquet M: Reporting results of cancer treatment. Cancer 37: 1648-1654, 1981.
19. Martindale Editorial Staff: The Extra Pharmacopeia. 29th Eds. London. Pharmaceutical Press pp 1586, 1989.
20. Wright J, Aldhous M, Franey C, et al: The effect of exogenous melatonin on endocrine function in man. Clin Endocrinol 24: 375-381, 1986.
21. Lissoni P, Barni S, Crispino S, et al: Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin, Oncol 25: 789-795, 1989.
22. Neri B, Fiorelli C, Moroni F, et al: Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. Cancer 73: 3015-3019, 1994.
23. Wright J, Aldhous M, Franey C, et al: The effect of exogenous melatonin on endocrine function in man. Clin Endocrinol 24: 375-381, 1986.
24. Terzolo M, Piovesan A, Puligheddu B, et al: Effects of long-term, low-dose, time-specified melatonin administration on endocrine and cardiovascular variables in adult men. J Pineal Res 9: 113-124, 1990.
25. Abbas K, Lichtman AH, Pober JS: The Cytokines. In: Cellular and Molecular Immunology, 2nd edition. By WB Saunders Company, Philadelphia, Pennsylvania, 1994.
26. Neri B, Brocchi A, Carossino AM, et al: Effects of melatonin administration on cytokine production in patients with advanced solid tumors. Oncol Rep 2: 45-47, 1996.
27. Sanchez De La Pena S, Halberg F, Lakatua D, et al: Rhythmic Pineal Hypophyseal-Adrenal-Intermodulation ex Vivo. In: Advanced in Chronobiology. Part A. J.E. Pauly, L.E. Scheving (Eds.). Alan R. Liss Inc, New York. pp. 421-422, 1987.
28. Morrey KM, McLachlan JA, SerkinCD et al: Activation of human monocytes by the pineal hormone melatonin. J Immunol 142: 2671-2680, 1993.
29. Kim S, Haas GP, Hillman GG: Development of immunotherapy for the treatment of malignancies refractory to conventional therapies. Cytok Mol Ther 2: 13-19,1996.
30. Finocchiaro ME, Nahmond VE, Launay JM: Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes. Biochem J 280: 727-731, 1991.
31. Blask DE: Melatonin in clinical oncology. In: Melatonin Biosynthesis, Physiological Effects and Clinical Applications. Yu HS, Reiter RJ (eds) CRC Press Boca Raton, Florida pp.464-470, 1993.
32. Lissoni P, Barni S, Tancini G, et al: A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasm other than renal cancer and melanoma. Br J Cancer 69: 196-199, 1994.